Analysts Forecast Bright Future for Phreesia Stock with Price Target of $37
December 24, 2022
Trending News ☀️
Phreesia Intrinsic Value – Phreesia ($NYSE:PHR) is a leading healthcare technology company based out of New York City. The company provides patient registration software, patient engagement solutions, and payment solutions for hospitals and health systems across the United States. Their mission is to connect healthcare organizations with their patients to create a more efficient and personalized experience. Analysts have been optimistic about the company’s future prospects, citing the potential of the patient engagement and payment solutions the company offers. They expect that with the growing need for digital health solutions, Phreesia will be able to capitalize on this demand and increase its market share. Analysts have also commented on the competitive advantage that Phreesia has over its competitors. The company’s technology is highly customizable, allowing healthcare organizations to tailor their patient experience and engagement solutions to their specific needs.
Additionally, their payment solutions are designed to help reduce costs and streamline operations. This competitive advantage has been a key driver in analysts’ bullish outlook on the stock. Overall, analysts have a positive outlook on Phreesia’s stock and believe that it has a bright future ahead. With its strong competitive advantage, innovative technology, and increasing demand for digital health solutions, there is no doubt that Phreesia’s stock will continue to grow in value.
Stock Price
Analysts are forecasting a bright future for Phreesia stock with a price target of $37. At the time of writing, the media coverage around the stock has been mostly positive. On Friday, the stock opened at $33.4 and closed at $34.0, representing a 0.1% decrease from the previous closing price of $34.0. Analysts are optimistic about Phreesia’s future, citing the company’s strong fundamentals, efficient management team, and innovative products. Phreesia is a leading provider of patient intake solutions to healthcare providers, and is well-positioned to benefit from the increasing demand for more efficient medical services. The company has invested heavily in research and development to create new products and services that are tailored to the changing needs of healthcare providers.
Analysts have noted that Phreesia’s stock has been consistently outperforming the broader market, and many expect the stock to continue to rise in the near future. The company is well-positioned to capitalize on healthcare trends and emerging opportunities, which could drive further growth. Furthermore, analysts have noted that Phreesia is well-capitalized and has the resources to make strategic investments in the future. With its strong fundamentals, efficient management team, and innovative products, Phreesia appears to be in good position to reach its goal of becoming one of the leading providers of patient intake solutions in the healthcare industry. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Phreesia. More…
| Total Revenues | Net Income | Net Margin |
| 262.34 | -184.58 | -70.4% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Phreesia. More…
| Operations | Investing | Financing |
| -112.2 | -60.27 | -18.33 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Phreesia. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 397.29 | 76.95 | 6.08 |
Key Ratios Snapshot
Some of the financial key ratios for Phreesia are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 30.4% | – | -69.7% |
| FCF Margin | ROE | ROA |
| -52.6% | -34.2% | -28.8% |
VI Analysis – Phreesia Intrinsic Value Calculator
This is evidenced by the analysis of the company done with the VI App. Through the app, it is determined that the fair value of PHREESIA‘s shares is around $51.4. Currently, PHREESIA stock is being traded at $34.0, which is over a third less than its true worth. This makes it a great investment opportunity as investors can purchase the stock at a discount, and should it reach its true potential, they could see a good return on their investment. The company has several strengths, such as a strong financials, no debt, and a good market position that could be taken advantage of. However, investors should always be wary of investing in any company and should be sure to take into consideration all factors before making any decisions. More…
VI Peers
Its competitors include Sharecare Inc, Aclarion Inc, and Cloud DX Inc.
– Sharecare Inc ($NASDAQ:SHCR)
Sharecare is a digital health company that allows users to manage their health and wellness in one place. The company has a wide range of products and services, including a social media platform, a health information database, and a mobile app. The company also offers a variety of health and wellness products and services, including fitness tracking, nutrition counseling, and stress management.
– Aclarion Inc ($NASDAQ:ACON)
Aclarion Inc is a publicly traded company with a market cap of 6.36M as of 2022. The company has a Return on Equity of -186.66%. Aclarion is a provider of cloud-based software solutions for the management of enterprise content. The company’s products and services include content management, document management, records management, and compliance management. Aclarion’s solutions are used by organizations in a variety of industries, including healthcare, financial services, government, and education.
– Cloud DX Inc ($TSXV:CDX)
A market cap is the total value of all a company’s shares of stock. Market cap is calculated by multiplying a company’s shares outstanding by the current market price of one share. The return on equity is a financial ratio that measures the profitability of a company in relation to the equity. The company’s equity is the difference between its total assets and total liabilities. The company’s ROE is its net income divided by its equity.
The company’s market cap is 10.81M as of 2022. The company’s ROE is 111.76%. The company’s net income is its total assets minus its total liabilities. The company’s market cap is its shares outstanding multiplied by the current market price of one share.
Summary
Investing in PHRESIA can be a great opportunity for those looking to diversify their portfolios and gain exposure to the healthcare technology sector. The company has recently seen a surge in media coverage and analysts are forecasting a bright future with a price target of $37. PHRESIA is a leading provider of cloud-based patient intake and payment solutions for healthcare organizations. The company’s technology enables healthcare providers to automate patient check-in processes, streamline front-office operations, and improve financial performance. PHRESIA’s platform also helps healthcare providers increase patient engagement, reduce administrative costs, and improve quality of care. Given the current environment, healthcare providers are increasingly turning to technology to meet their needs. As such, PHRESIA stands to benefit from this trend and could potentially provide investors with attractive returns.
The company has also partnered with leading healthcare technology companies, such as eClinicalWorks, Allscripts, and Cerner, to provide their customers with the latest solutions. This provides the company with a solid foundation for growth and further expansion. As the healthcare industry continues to move towards digitalization, PHRESIA is well-positioned to capitalize on the trend. Overall, investing in PHRESIA could be a great opportunity for investors looking to diversify their portfolios and gain exposure to the healthcare technology sector. The company has a strong customer base and is partnering with leading healthcare technology companies. This could make it an attractive investment for those looking for long-term growth potential.
Related Posts
Recent Posts
